Expert Insight View All
Meeting Highlight View All

The PROfound promise of genomics in mCRPC management


Dr. Joaquin Mateo

Medical Oncologist and Attending Physician,
Vall d’Hebron University Hospital, Barcelona
Principal Investigator,
Prostate Cancer Translational Research Group,
Vall d’Hebron Institute of Oncology

Research spotlight View All

Navigating genetic testing in prostate cancer: An insight into the joint HKUA-HKSUO consensus recommendations

In 2019, prostate cancer (PC) was ranked the third most frequently diagnosed cancer among men in Hong Kong.1 Though genetic testing has not been previously considered a routine approach of PC patient care, recent sequencing studies revealed that about 11.8% of metastatic PC (mPC) patients carried in

31 Aug 2023

Front Oncol. 2022.

Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC. Genetic testing and its clinical application in prostate cancer management: Consensus statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. Front Oncol. 2022;12:962958.